Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.11 EPS, up 9.09% or $0.01 from last year’s $-0.12 per share.

At the moment 5 analysts are watching Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), 1 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 3 analysts have a mean sales target of 0.09 million. For the quarter ending Sep-16, 3 analysts have a mean sales target of 0.09 million whilst for the year ending Dec-16, 3 analysts have a mean target of 0.37 million.

In terms of earnings per share, 3 analysts have a -0.12 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 3 analysts have a -0.11 EPS mean target and for the quarter ending Sep-16 there are 4 estimates of -0.45 EPS.

The biggest institutional shareholders in Idera Pharmaceuticals, Inc. include Baker Bros Advisors LP which owns 7 million shares in the company valued at $21.58 million. Putnam Investment Management,LLC is the second biggest holder with 6 million shares currently valued at 17.70 million whilst Vanguard Group Inc has 3 million shares valued at 10.80 million.

Total shares held by institutions as of the most recent company filings are 44,610,518 with a reported 3,219,889 bought and 5,137,280 sold. These holdings make up 36.78% of the company’s outstanding shares.

Currently insiders hold 1,585,207 shares in the business which makes up 1.31% of shares. The biggest holder currently is Youssef El-Zein who owns 506,023 shares (0.42% of those outstanding), whilst Mr. James A. Geraghty holds 415,649 (0.34% of shares outstanding) and Vincent J. Milano holds 246,527 (0.20% of shares outstanding).

The stock increased 2.24% or $0.03 during the last trading session, hitting $1.85. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has fallen 92.43% over the past 6 months and is downtrending.